You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on prostate cancer.
Metastatic prostate cancer patients with BRCA, PALB2, FANCA, and CDK12 mutations had an improved response than those without such mutations, a study showed.
The team envisions developing an assay to guide targeted treatment for metastatic castration-resistant prostate cancer patients.
A Phase II study suggests immune-related expression signatures and other immune markers may help find metastatic prostate cancer cases with better checkpoint blockade response.
Myriad has partnered with Japanese firm SRL, a subsidiary of Miraca Group, to commercialize its BRACAnalysis Diagnostic System in Japan.
The group now states that men with unfavorable intermediate-risk or high-risk disease can consider testing with Myriad's Prolaris or GenomeDx's Decipher.
The company has seen promising activity for the drug in KRAS-mutated metastatic colorectal cancer, and biomarker-defined patient subgroups with castration-resistant prostate cancer and AML.
The foundation-funded initiative from Jackson Laboratories has advanced a model for educating oncologists and providing access to tumor genomic profiling in the community setting.
The FDA granted priority review status to rucaparib for prostate cancer patients with BRCA1/2 mutations.
The LCD will provide coverage for the Decipher Prostate Biopsy genomic test for men with both favorable and unfavorable intermediate-risk prostate cancer.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.